Dementia occurs in up to 80% of people with idiopathic Parkinson disease (PD) and substantially increases morbidity, mortality and cost of care for these individuals. In fact, it may be the most important factor leading to residential care placement. Yet, treatment of dementia in PD remains nearly non-existent, making this one of the great unmet needs for the nearly one million people affected by PD in North America. A major roadblock in developing and testing new treatments for dementia in PD is identification of the cause of dementia in a given individual - critically important to test therapies in relatively homogenous groups. This is a particular challenge in PD since dementia may be caused by either underlying cortical a-synuclein (a-syn) pathology or co-existing Alzheimer's (AD) pathology that includes abnormal deposition of A? and tau proteins. Our recent studies suggest that this may be an oversimplification. A? may be an independent factor, not necessarily related to tauopathy in PD, producing 3 groups of PD dementia: 1) primarily cortical synucleinopathy, 2) primarily cortical synucleinopathy with abnormal A? and 3) much less commonly cortical synucleinopathy with abnormal A? and tauopathy. We will test the hypotheses that behavior, PET, MRI, genetic and CSF biomarkers will permit identification of these causes and help predict onset of dementia in PD. We propose to test these hypotheses with a longitudinal follow up of people with PD with and without dementia and matched healthy controls. The multidisciplinary team will do evaluations including standard clinical evaluation, clinical dementia ratings, neuropsychological testing, volumetric MRI based measures of regional atrophy, resting state functional connectivity MR of brain networks, PET PIB in vivo measures of amyloid, CSF measures of relevant proteins (a-syn, A?42 and tau), postmortem neuropathology and quantified analysis of a-syn, A? and tau in selected brain areas. The postmortem analyses of brains will permit validation of the biomarkers. This also will provide the opportunity to make connections between imaging findings, behavior and regional protein expression in the brain. This study will validate biomarkers of specific pathologies underlying dementia in PD and that predict dementia onset. Our approach, borrowed heavily from studies in AD, will provide the framework for testing to-be-developed measures such as new CSF proteins, imaging methods or genetic signatures to determine whether they are more reliable or earlier biomarkers of dementia in PD. The ultimate goal is to use these biomarkers to test the efficacy of new therapies that will prevent dementia in PD.

Public Health Relevance

Parkinson disease (PD) is a progressive neurologic degenerative disease affecting nearly one million people in North America. These people have very high risk for development of dementia that adds substantial morbidity, mortality and economic burden to patients, families and society. This proposal will investigate the clinical manifestations of different forms of dementia, clarify the underlying causes and develop biomarkers that herald the onset of dementia. These steps are critical for development of effective treatment of dementia associated with PD.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Clinical Neuroscience and Neurodegeneration Study Section (CNN)
Program Officer
Babcock, Debra J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Schools of Medicine
Saint Louis
United States
Zip Code
Ibanez, Laura; Dube, Umber; Saef, Benjamin et al. (2017) Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. BMC Neurol 17:198
Takeda, Atsushi; Perlmutter, Joel S (2017) Striatal molecular imaging of presynaptic markers: Ready, fire, aim. Neurology 88:1388-1389
Ibanez, Laura; Dube, Umber; Budde, John et al. (2017) TMEM230 in Parkinson's disease. Neurobiol Aging 56:212.e1-212.e3
Myers, Peter S; McNeely, Marie E; Koller, Jonathan M et al. (2017) Cerebellar Volume and Executive Function in Parkinson Disease with and without Freezing of Gait. J Parkinsons Dis 7:149-157
Martin, W R W; Hartlein, J; Racette, B A et al. (2017) Pathologic correlates of supranuclear gaze palsy with parkinsonism. Parkinsonism Relat Disord 38:68-71
Eisenstein, Sarah A; Bogdan, Ryan; Love-Gregory, Latisha et al. (2016) Prediction of striatal D2 receptor binding by DRD2/ANKK1 TaqIA allele status. Synapse 70:418-31
Jin, Hongjun; Zhang, Xiang; Yue, Xuyi et al. (2016) Kinetics modeling and occupancy studies of a novel C-11 PET tracer for VAChT in nonhuman primates. Nucl Med Biol 43:131-9
Norris, Scott A; Jinnah, H A; Espay, Alberto J et al. (2016) Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Mov Disord 31:1874-1882
Yue, Xuyi; Bognar, Christopher; Zhang, Xiang et al. (2016) Automated production of [ยน?F]VAT suitable for clinical PET study of vesicular acetylcholine transporter. Appl Radiat Isot 107:40-46
Davis, Albert A; Andruska, Kristin M; Benitez, Bruno A et al. (2016) Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression. Neurobiol Aging 37:209.e1-209.e7

Showing the most recent 10 out of 89 publications